Press Releases

Our latest news and press releases

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

Read more

Cellectis to Report Third Quarter 2022 Financial Results

Read more

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Read more

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

Read more

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Read more

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Read more

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more